In line with the notion that the regulation of classical and alternative CR ligands follows different control mechanisms, the two-dimensional t-SNE plot cluster analysis but also the Kaplan–Meier survival curves of AML patients with comparable clinical characteristics (Suppl. Table 3, Suppl. Fig. 3) indicated that AML patients with a poorer prognosis rather display a CD86low CD112/CD155high phenotype, whereas AML patients with an overall better outcome rather exhibited a CD86high CD112/CD155low phenotype (p ≤ 0.1, Fig. 3C). The gene discussed is NECTIN2; the disease is acute myeloid leukemia.